Aura Biosciences Q2 2025 net loss $27.0M; cash $177.3M; Phase 3 CoMpass nearing enrollment end

Aura Biosciences, Inc.

2025-Q2 EPS reported -$1.01 vs consensus -$0.47 ▼ miss (-116.4%)

Net loss $27.0M in Q2 2025 vs $20.3M in Q2 2024; R&D expenses rose to $22.9M from $16.9M.
Cash and marketable securities $177.3M; $75M equity financing closed; cash runway into first half 2027.
Phase 3 CoMpass trial in early choroidal melanoma actively enrolling; >240 patients pre-screened; enrollment may complete by end of 2025.
Phase 1b/2 NMIBC trial actively enrolling; new bel-sar formulation patent filed for convenient in-office use.
Phase 2 trial in metastases to choroid protocol amended to include all solid tumors; initial data expected 2025.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.